Results for tag: "Leber Congenital Amaurosis"

Leber Congenital Amaurosis (LCA) is a rare, inherited retinal disorder that affects the vision of children from birth. It is caused by mutations in one of several genes, leading to a loss of photoreceptor cells in the retina. This results in a progressive decline in vision, including night blindness, decreased visual acuity, and sensitivity to light. Treatment options for LCA are limited, and include gene therapy, stem cell therapy, and retinal prostheses. Optical treatments for LCA are focused on preserving and restoring vision. These include corrective lenses, low vision aids, and vision rehabilitation. Additionally, research is being conducted on the use of artificial intelligence and machine learning to improve the accuracy of diagnosis and treatment. Companies in the LCA market include Spark Therapeutics, GenSight Biologics, Nightstar Therapeutics, and Applied Genetic Technologies Corporation. Show Less Read more